# Japan vision-restoration research — source note

Reviewed September 17, 2026. Original supplied URL: https://youtu.be/lbBIT9h8qjk?is=WZ5sp3zGA1jw46T-
Canonical: https://www.youtube.com/watch?v=lbBIT9h8qjk
Title: Japan's New Invention Could Cure Blindness
Channel: Polarisyn; upload date 20260917; duration 1521 seconds.

## Capture
Metadata, English auto-captions and thumbnail were captured. Caption spelling is machine-generated and was checked against named programmes and primary papers. Full caption text, source-page extracts, trial records and regulatory PDFs are retained in the private research archive. They are not republished wholesale. Public article and evidence ledger contain original paraphrase with primary links. Thumbnail language and medical-themed imagery are promotional, not evidence of clinical outcomes. No full video rehosting or purchase links.

## Evidence map and limits
Six programme groups were checked separately: RV-001; RPE transplants; retinal organoids/DSP-3077; corneal sheets; OUReP; MCO-010. Primary publications, registries and regulator documents take precedence over the video. Sponsor releases are identified as such, not treated as independent clinical review.

Later Japanese registry outcomes for retinal organoids extend to 208 weeks, with no ETDRS visual-acuity improvement in either participant. RPE no-systemic-immunosuppression claims must not omit local steroid use or reported immune reactions. Four-patient corneal results concern limbal stem-cell deficiency, not retinal degeneration. RV-001 interim six-person data are not the registry's updated target of 45. MCO-010 January designations and September sponsor-reported BLA filing are not marketing approval. OUReP human efficacy and a patient price were not verified; an exact-name ClinicalTrials.gov search is not exhaustive for Japanese/device registrations. Exact DSP-3077 first-operation date/site were not established and are not claimed.

Some web-extraction requests returned incomplete pages or failures. Direct requests recovered the Japanese registry results, regulatory PDFs and donor-RPE full paper. An FDA prescribing-information download was access-blocked; the FDA product page and official document link are supplied, without inventing a local copy. The source video also includes speculative commercial, pricing and universal-efficacy claims not established by the clinical evidence.

Article is educational, not medical advice. Meaningful early progress is distinct from general efficacy, long-term safety and regulatory authorization.